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Summary 
Epstein-Barr virus (EBV), a human herpes virus with oncogenic potential, persists in B lymphoid 
tissues and is controlled by virus-specific  cytotoxic T lymphocyte (CTL) surveillance. On reactivation 
in vitro, these CTLs recognize EBV-transformed lymphoblastoid cell lines (LCLs) in an HLA 
class I antigen-restricted fashion, but the viral antigens providing target epitopes for such recognition 
remain largely undefined. Here we have tested EBV-induced polyclonal CTL preparations from 
16 virus-immune donors on appropriate fibroblast targets in which the eight EBV latent proteins 
normally found in LCLs (Epstein-Barr  nuclear antigen [EBNA] 1, 2, 3A, 3B, 3C, leader protein 
[LP],  and latent membrane protein [LMP]  1 and 2)  have been expressed  individually from 
recombinant vaccinia virus vectors. Most donors gave multicomponent responses with two or 
more separate reactivities against different viral antigens. Although precise target antigen choice 
was clearly influenced by the donor's HLA class I type, a subset of latent proteins, namely EBNA 
3A, 3B, and 3C, provided the dominant targets on a range of HLA backgrounds; thus, 15 of 
16 donors gave CTL responses that contained reactivities to one or more proteins of this subset. 
Examples of responses to other latent proteins, namely LMP 2 and EBNA 2, were detected through 
specific HLA determinants, but we did not observe reactivities to EBNA 1, EBNA LP, or LMP 
1. The bulk polyclonal CTL response in one donor, and components of that response in others, 
did not map to any of the known latent proteins, suggesting that other viral target antigens 
remain to be identified. This work has important implications for CTL control over EBu 
malignancies where virus gene expression is often limited to specific subsets of latent proteins. 
C 
TLs can play an important role in controlling virus in- 
fections, particularly as effectors of long-term immune 
surveillance against viruses that persist in the infected host. 
This is reflected in the frequency with which reactivation of 
persistent infections is observed in patients whose CTL re- 
sponses are suppressed (1). Work in model systems first showed 
that the dominant components of virns-induced CTL popu- 
lations are CD8 + MHC class I-restricted T  cells (2)  and 
that these effectors  recognize peptide fragments of endo- 
genously synthesized viral antigens presented on the target 
cell surface as a complex with MHC class I molecules (3, 
4). In seeking to understand viral infections of humans, there- 
fore,  it is important in each case to know both the range 
of viral antigens that can induce effective CTL responses, and 
the influence of HLA class I polymorphism upon viral target 
antigen choice. 
The present study concerns human CTL responses to EBV. 
This lymphotropic herpes virus has potent cell growth-trans- 
forming activity both in vivo and in vitro, is the causative 
agent of infectious mononucleosis, and is strongly linked to 
at least three lymphoid malignancies: endemic Burkitt's lym- 
phoma, the immunoblastic B cell lymphomas seen in im- 
munocompromised  patients, and a subset of cases of Hodgkin's 
Disease, as well as to the epithelial tumor, nasopharyngeal 
carcinoma (5-10).  Despite its potential pathogenicity, EBV 
is widespread in human populations where it is carried by 
the vast majority of individuals as a life-long and largely asymp- 
tomatic infection. Significantly, asymptomatic virus carriage 
is associated with the presence in T cell memory of relatively 
large numbers of EBV-specific CTL precursors that can be 
reactivated  in vitro by challenging with autologous virus- 
infected B cells (11). The CTL preparations thus produced 
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(LCLs)  1 in a HLA class I antigen-restricted fashion. Thus, 
although EBV is a complex virus with the capacity to en- 
code up to 100 proteins, the dominant targets for CTL re- 
sponses  appear to lie within that smaller set of viral gene 
products (the so-called EBV latent proteins) that are consti- 
tutively expressed in LCLs. These are now known to include 
six nuclear antigens, Epstein-Barr nuclear antigen [EBNA] 
1,  2,  3A, 3B, 3C, and leader protein (LP), and two latent 
membrane proteins, latent membrane protein [LMP] 1 and 
2, each of which is antigenically distinct and encoded by a 
uniquely spliced mRNA (12); note that two forms of LMP 
2 are independently expressed  in LCLs, but in the present 
context attention can be confined to the full-length LMP 2A 
protein since this contains within it all of the primary se- 
quence of the smaller LMP 2B form. 
To analyze CTL target antigen choice in this viral system, 
we aimed to develop a panel of recombinant vaccinia viruses 
capable of expressing the individual latent proteins from the 
relevant cDNAs. An earlier study had concentrated on recom- 
binants expressing either EBNA  2  or 3A,  both antigens 
showing some sequence divergence between type 1 and 2 EBV 
isolates (13, 14), and had formally identified examples of rare 
EBV type-specific CTL reactivities that mapped to these par- 
ticular proteins (15, 16). However, it was already clear that 
most EBV-induced CTL responses,  certainly when screened 
as polyclonal populations, recognized both type I and 2 virus- 
transformed cell lines (15, 17). The antigenic specificity of 
these dominant responses  therefore remained to be defined. 
Here we describe the construction and use of a full panel 
of EBV latent gene/vaccinia recombinants in the analysis of 
EBV-induced CTL preparations from each of 16 virus-immune 
individuals of  known HLA type. Although the observed target 
antigen choice differs between individuals in a HLA class 
I-related manner, there nevertheless does appear to be a hier- 
archy among the EBV latent proteins with respect  to their 
immunogenicity for the CTL repertoire. This has important 
implications for the feasibility of CTL control over those EBV- 
positive malignancies where only particular subsets  of the 
full spectrum of latent proteins are expressed. 
Materials and Methods 
Generation of Vaccinia Virus Recombinants.  All coding sequences 
for EBV latent proteins were ofB95.8 virus (type I isolate) origin 
(18), and Fig. 1 A illustrates the general position and orientation 
of the relevant coding sequences on a linear BamHI restriction map 
of the B95.8 EBV genome. For simplicity, the detailed exon struc- 
ture of each transcript, as expressed in a natural EBV infection, 
has been omitted. All transcripts show complex splicing; in partic- 
ular, the full-length LMP 2 protein is encoded by a transcript (19) 
in which the first exon is derived from sequences near the LMP 
1 gene and the first splice traverses the terminal repeats (Fig. 1 A, 
1 Abbreviations used in this paper: EBNA, Epstein-Barr nuclear antigen; 
LCL, lymphoblastoid  cell  line;  LMP, latent  membrane  protein; LP, leader 
protein. 
crosshatched boxes) which are fused together on circularization of 
the genome in Intently infected cells. For all vaccinia  recombinants 
(~cept that encoding EBNA 1), the EBV sequences of  interest were 
cloned into the SmaI cloning site of the pSC11 insertion vector 
downstream of the P7.5 vaccinia  early/late promoter, as illustrated 
in Fig. 1 B. This is the promoter of choice for CTL target antigen 
expression from recombinant vaccinia vectors (20). Details of the 
EBV sequences  present in the EBNA 2 vaccinia  recombinant (Vacc- 
E2), in the EBNA 3C recombinant (Vacc-E3C), and in the EBNA 
LP recombinant (Vacc-LP) are already published (16), as are those 
present in the EBNA 3A recombinant (Vacc-F.3A)  and in the EBNA 
3B recombinant (Vacc-E3B) (21). The LMP 1 recombinant (Vacc- 
LMP 1) contained the full-length LMP I cDNA (22), and the LMP 
2 recombinant (Vacc-LMP 2) contained the full-length LMP 2A 
cDNA (19). 
It was not possible to generate a viable EBNA 1 vaccinia  recom- 
binant using the above protocol. As an alternative, therefore, the 
EBNA I recombinant (Vacc-E1) was constructed with the EBNA 
1  open  reading  frame  BKRF  1  (18; genomic  positions 
107820-110176) under the control of a T7 promoter, and was used 
in conjunction  with a T7 RNA polymerase-encoding vaccinia 
recombinant Vacc-TT. The EBNA 1 open reading frame was cloned 
in the BamHI site of pTF7-5 (23) after both sets of ends had been 
repaired with T4 DNA polymerase.  From this plasmid, designated 
pT7-E1, the EBNA 1 open reading frame, T7 promoter, and T7 
termination signal was excised along with minimal flanking vac- 
cinia virus sequences using SspI and inserted into the SmaI site 
of pSC11. Both orientations of TT-EBNA 1 relative to the P7.5 
promoter were transfected into vaccinia-infected  cells as described 
(16). Only the orientation with T7-EBNA 1 transcription oppo- 
site to the P7.5 promoter produced viable virus. 
Screening.for Expression of EBv Latent Proteins.  Skin  fibroblast 
cultures from relevant donors were exposed to recombinant vac- 
cinia virus (multiplicity of infection [MOI] 10) for 2 h, then addi- 
tional culture medium added for a further 16 h. Infected cultures 
were then harvested  by trypsinization, the cells washed three times 
in PBS, and either used to make protein extracts or microscope 
slide preparations. Protein extracts were separated by SDS-PAGE, 
immunoblotted, and probed for expression of the relevant EBV pro- 
tein  using  appropriate monospecific or  monoclonal antibodies 
(24-27). Slide  preparations were fixed for 10 min in methanol/ace- 
tone (1:1 at -20~  or, for testing LMP 2 expression (28), in ace- 
tone (at 4~  before immunofluorescence  staining using the same 
range of antibodies. 
CTL Pre~rations.  The 16 donors used in the present work were 
known from previous analysis  (27) to be all carrying a type 1 virus 
isolate, i.e., of the same type as the B95.8 laboratory strain (18). 
PBMC  from  these HLA-typed donors were cocultivated with 
~/-irradiated stimulator cells of the autologous B95.8 virus-trans- 
formed LCL and the resultant EBV-specific  polyclonal  CTL prepa- 
rations maintained in IL-2-conditioned  medium as described (29); 
EBV-specific CTL clones were generated from cocultures at day 
3 poststimulation by seeding in semi-solid  agar, and subsequently 
could be maintained for a limited period as described (15). 
Allospecific CTL preparations, recognizing defined HLA class 
I antigens as targets, were generated for control experiments as 
previously described (30). 
Cytotoxicity Assays.  Monolayer  cultures of fibroblasts were es- 
tablished from most CTL donors and from other HLA-typed indi- 
viduals from small skin biopsies and the cells exposed to recom- 
binant vaccinia virus as above (2  x  106 cells per 9-cm petri dish). 
Cells were harvested by trypsinization 18 h postinfection and la- 
beled for 1 h with SlCrO4, washed three times, and used as targets 
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assay were harvested into  1%  formaldehyde before counting. 
Results 
Expression  of EBV Latent Proteins  in  Vaccinia-infected Fibre- 
blasts.  The recombinant vaccinias carrying individual EBV 
latent genes (Fig.  1) were screened for expression of the rele- 
vant EBV protein in human fibroblast target cells. Fig.  2 A 
illustrates  results  obtained  from fibroblasts  18  h  postinfec- 
tion with recombinant vaccinias encoding EBNA  1,  2, LP, 
3A,  3B,  and  3C,  respectively.  Immunoblots  of protein  ex- 
tracts were probed with monospecific antibody preparations 
(to EBNA  1,  3A,  and 3B) or mAbs (to EBNA 2,  LP,  and 
3C).  Generally,  levels  of expression  were  markedly higher 
than that seen for the corresponding  EBV latent protein in 
extracts  of virus-transformed  LCL  cells,  and  immunoblot- 
ting revealed both the appropriately sized protein and a number 
of antigenically related minor species of different molecular 
masses. Note that EBNA LP is expressed as a ladder of pro- 
teins,  probably reflecting  heterogeneity within  the Vacc-E- 
LP virus preparation itsdf because of recombination within 
the repeated BamHI W  exons of the EBNA LP coding se- 
quence (16, 31). Fig. 2 B similarly illustrates efficient expres- 
sion of LMP 1 from the Vacc-LMP 1 recombinant,  detected 
by immunoblotting using the mAbs CS1-4. Appropriate an- 
tisera were not available for screening LMP 2 expression by 
immunoblotting, but fibroblasts infected with Vacc-LMP 2 
gave  specific  cytoplasmic/membrane immunofluorescence 
staining using a rabbit antiserum against a LMP 2 fusion pro- 
tein (28). 
Expression of the other EBV latent proteins was also ex- 
amined by immunofluorescence at the single-cell  level, showing 
in each case that >90% of the fibroblasts expressed the rele- 
vant target protein by 18 h postinfection. We therefore rou- 
tinely used this time point to initiate the CTL assays and, 
for each assay, made reference  slides  from aliquots of target cells. 
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Figure 1.  (.4)  Diagrammatic representation of the positions of the EBV 
latent genes on the viral genome. The B95.8-strain EBV genome is shown 
in linear form between terminal repeat sequences (crosshatched  boxes) with 
BamHI restriction sites indicated by vertical markers and BamHI restric- 
tion fragments identified by the letters A-Z and a-f. The relative position 
and orientation of the coding sequences for each of the EBV latent pro- 
reins are indicated diagmmmatica~y;  for simpl/city,  the detailed exert struc- 
ture of each latent mRNA has been omitted. (B) Diagrammatic represen- 
tation of the vaccinia  insertion vector  pSCll showing the site  of  introduction 
of individual EBV latent genes downstream of the vaccinia  P7.5 early/late 
promoter. The LacZ indicator gene is driven from the vaccinia Pll late 
promoter.  Recombination into  the wild-type vacdnia virus genomic is 
directed by flanking sequences of the vaccinia  virus thymidine kinase (TK) 
gene. 
Figure  2.  (.4)  Detection by immunoblotting of EBNAs expressed  from 
recombinant vacdnia viruses. Immunoblots of protein e~tracts from fibre- 
blasts infected  with EBV latent gene: vaccinia  recombinams.  Replicate  blots 
were  probed  either  with  affinity-purified monospecific human  anti- 
bodies to EBNA 1 (27), with the EBNA 2-specific mAb PE2 (25), with 
the EBNA LP-specific  mAb JF186 (16), with affinity-purified  human an- 
tibodies to EBNA 3A (26) or to EBNA 3B (26), or with the EBNA 
3C-specific mAb E3C.A10 (M. Rowe, unpublished results). Note that 
the panel of recombinant vaccinias  used here included Vacc-E2.2, which 
expresses the type 2 EBNA 2 protein (16). Each immunoblot  contains 
control tracks of protein extracts from the EBV-negative  BJAB cell line 
and from a standard LCL. In each case the EBNA protein being detected 
by immunoblotting  is identified to the right of the blot.  (B) Detection 
by immunoblotting or immunofluorescence  of LMPs expressed  from recom- 
binant  vaccinia viruses. The immunoblot  on the left was probed with 
the LMP 1-specific mAbs CS1--4 (24). The photographs  on  the right 
illustrate immunofluorescence staining  of Vacc-LMP 2-infected  fibre- 
blasts, and Vacc-TK--infected controls, with an LMP 2-specific rabbit 
antiserum (28). 
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broblasts.  CTL preparations were generated from 16 donors 
of known HLA class I antigen type and, as described in ear- 
lier work (29),  screened on a panel of standard target lines, 
including the autologous and various aUogeneic  LCLs,  to 
confirm EBV specificity and to identify the HLA class I re- 
striction of the major component reactivities.  Only CTL 
preparations showing the characteristic properties of virus 
specificity and HLA class I restriction were used in the present 
study. Such CTLs were then assayed on autologous fibro- 
blasts and/or on appropriate HLA class I-matched fibroblasts 
after infection of the targets with the full panel of EBV/vac- 
cinia recombinants. A  number of additional controls were 
also included in the analysis. Thus, both in preliminary ex- 
periments and on several occasions throughout the main study, 
we screened the complete panel of fibroblast targets with al- 
lospecific effectors to ensure that infection with the various 
recombinant viruses did not significantly alter the cells' sus- 
ceptibility to cytolysis per se. A number of allospecific CTL 
preparations, reactive against HLA-A2, B27, or B35 were tested 
against appropriately matched fibroblasts  and similar levels 
of lysis were observed whether or not the targets were in- 
fected with the present panel of recombinant vaccinias (data 
not shown). More importantly, where EBV-specific CTLs 
from a particular donor recognized a particular EBV target 
antigen on autologous or HLA antigen-matched fibroblasts 
(see below), we carried out parallel  control experiments to 
confirm that HLA-mismatched CTL/fibroblast combinations 
involving either these effectors or these targets did not lead 
to  similar lysis. 
Fig. 3 illustrates the method of analysis with reference to 
the CTL response from one of the 16 virus-immune donors 
studied, donor CMc (HLA-A2, All,  B8, B44).  Polyclonal 
CTL preparations from this individual were known from prior 
screening on LCL targets to contain HLA-A11-, B8-, and B44- 
restricted components; when tested on autologous fibroblasts, 
these preparations consistently yielded the pattern of results 
shown in Fig.  3 a. Infection with Vacc-E3A,  Vacc-E3B, or 
Vacc-E3C sensitized the target cells to lysis, whereas infec- 
tion with the other recombinants produced the same very 
low background lysis as for uninfected fibroblasts.  We then 
tested these same effectors on HLA-B8-matched target cells 
and observed sensitization both with Vacc-E3A and with Vacc- 
E3B recombinants (Fig. 3 b); this result was reproducible and 
was obtained on fibroblasts from two different donors matched 
with donor CMc only through HLA-B8. The same assays 
conducted on HLA-All-matched fibroblasts revealed lysis only 
of Vacc-E3B-infected targets (Fig.  3 c), and again, assays on 
two different All-positive fibroblast lines gave the same re- 
suit. Because the panel of available fibroblast lines was limited, 
it was not possible to study the B44-restricted response of 
donor CMc in isolation. In these circumstances we turned 
to CTL clones established from this same donor and showing 
restriction through HLA-B44;  the results from one repre- 
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Figure 3.  Analysis of EBV target 
antigens  recognized  by  virus- 
induced  CTL  preparations  from 
donor CMc  (HLA-A2, All, BS, 
B44).  In ~ch case effector  CTLs 
were tested against autologous or 
appropriately HLA-matched fibro- 
blasts either uninfected (uninf),  or 
after infection with the recombinant 
vaccinias indicated. Control targets 
included the autologous LCL and 
allogeneic  LCLs  either  HLA 
matched with donor CMc (as indi- 
cated) or mismatched (alia). (a) Poly- 
clonal CTLs tested on autologous 
fibroblasts.  (b)  Polyclonal  CTLs 
tested on HLA-BS-matched fibro- 
blasts. (c) 1)olyr.lon,~l  CTLs tested on 
HLA-All-matched fibroblasts.  (d) 
A HLA-B44-restricted  CTL clone 
tested  on  autologous  fibroblasts. 
E/T ratios were (a) 11:1, 6:1 in ad- 
jacent columns;  (b)  10:1, 5:1; (c) 
12:1; and (d) 3:1. 
160  Target Antigens for Epstein-Barr Virus-specific CTLs sentative clone of this kind are shown in Fig. 3 d and reveal 
specific sensitization of autologous fibroblasts to B44-restricted 
lysis after Vacc-E3C infection. It is clear, therefore, that the 
individual components of the EBV-induced CTL response in 
donor CMc map to different EBV latent proteins, and that 
a single HLA-restricting determinant (in this case, HLA-B8) 
may present target epitopes from more than one latent protein. 
The CTL preparations obtained from a second donor MS 
(HLA-A2, A2, B18,  B44) were known from screening on 
LCL  targets  to  be  dominated by  HLA-A2-  and/or  B44- 
restricted components, and their analysis on vaccinia-infected 
fibroblasts is illustrated in Fig. 4. Most polyclonal prepara- 
tions from this donor contained both A2- and B44-restricted 
components, and, when tested on autologous fibroblasts in- 
fected with the recombinant vaccinias,  such effectors lysed 
targets expressing either EBNA 3B, EBNA 3C,  or LMP 2 
(Fig. 4 a). However, some CTL activations preferentially in- 
duced B44-restricted responses, and in these cases we observed 
lysis only of Vacc-E3C fibroblasts (Fig.  4 b); this result was 
reproducibly seen with two different sources of B44-matched 
fibroblasts.  In other CTL activations from donor MS,  the 
HLA-A2-restricted response proved to be dominant, and such 
effectors specifically  recognized Vacc-E3B-  and Vacc-LMP 
2-infected targets (Fig.  4 c). Subsequently, we attempted to 
separate these EBNA 3B- and LMP 2-directed responses by 
cloning; however, of several HLA-A2-restricted CTL clones 
obtained, all showed recognition only of LMP 2; results from 
one such clone are illustrated in Fig. 4 d. Note that donor 
MS, like all the A2-positive donors in the present study, was 
subtyped as A2.1, the most common subtype of HLA-A2 (32). 
Detailed results are also presented for two further EBV- 
immune individuals, IB and SC, both included in the present 
panel of donors because they were homozygous at HLA-A 
and B loci. Donor IB (HLA-A2, B7) gave polyclonal CTL 
preparations, containing both HLA-A2- and B7-restricted com- 
ponents, which when assayed on autologous fibroblasts were 
reactive against EBNA 3C and LMP 2  (data not shown). 
When  such  polyclonal populations  were assayed  on  A2- 
matched fibroblasts,  clear results were obtained showing that 
the A2-restricted response was directed against an epitope 
from LMP 2.  In the absence of an appropriate B7-matched 
fibroblast target line, we studied the B7-restricted compo- 
nent of the donor IB CTL response by testing derived CTL 
clones on autologous fibroblasts.  Fig. 5 b shows representa- 
tive results from one of several B7-restricted clones, all of 
which selectively recognized Vacc-E3C-infected cells. A second 
homozygous donor, SC (HLA-A2, B27 subtype B27.05), gave 
polyclonal CTL preparations, which when tested on allogeneic 
LCLs,  were dominated by B27-restricted components with 
little or no A2-restricted activity. When B27-restricted prepa- 
rations were tested on recombinant vaccinia-infected fibro- 
blasts, they were found to contain both EBNA 3A- and EBNA 
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Figure  4.  Analysis of EBV target 
antigens  recognized  by  virus- 
induced  CTL  preparations  from 
donor MS (HLA-A2, A2; B18, B44) 
using protocols as in Fig. 3. (a) Poly- 
clonal CTL preparation containing 
both HLA-A2- and B44-restricted 
components tested on autologous 
fibroblasts; (b) polyclonal CTL prep- 
aration containing only the B44- 
restricted  component  tested  on 
HLA-B44-matched fibroblasts;  (c) 
polyclonal CTL  preparation con- 
taining only the A2-restricted com- 
ponent tested on autologous fibro- 
blasts;  (d)  a  HLA-A2-restricted 
CTL  clone tested on  autologous 
fibroblasts. E/T ratios were (a) 12:1, 
(b) 9:1, (c) 3:1, and (d) 2:1. 
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Figure 5.  Analysis of EBV target antigens recognized by virus-induced 
CTL preparations from donor IB (HLA-A2; B7) using protocols as in Fig. 
3. (a) Polyclonal CTLs tested on HLA-A2-matched fibroblasts; (b) an HLA- 
B7-restricted CTL clone tested on autologous fibroblasts. E/T ratios were 
(a) 6:1 and (b) 3:1. 
3C-reactive components (Fig. 6 a). The EBNA 3C compo- 
nent was consistently the stronger  of the two, and indeed 
all of the B27-restricted CTL clones from this donor showed 
EBNA 3C reactivity; typical results from one such clone are 
illustrated in Fig.  6  b.  In addition,  clonal analysis  also re- 
vealed the presence of an A2-restricted  component  in the 
memory CTL response of donor SC, which,  at the clonal 
level,  consistently mapped  to LMP 2  (e.g.,  see Fig.  6 c). 
In all, EBV-specific CTL preparations  from 16 virus-immune 
donors were analyzed using the methods illustrated above. 
In  15/16 cases,  one or more EBV latent  proteins could be 
identified as targets for the CTL response; furthermore,  the 
majority of the individual latent protein-specific components 
identified could be assigned a definite HLA-restricting  an- 
tigen.  The overall data are presented in  summary  form in 
Table 1. A number of points need to be made in this context. 
First,  autologous fibroblasts were available  as targets  from 
13 of the  15 donors  shown in Table 1,  and in all  but one 
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Figure 6.  Analysis of EBV target antigens recognized by virus-induced 
CTL preparations from donor SC (HLA-A2; B27) using protocols as in 
Fig. 3. (a) Polyclonal CTL preparation containing only B27-restricted com- 
ponents tested on autologous fibroblasts; (b) an HLA-B27-restricted CTL 
clone tested on autologous fibroblasts; (c) an HLA-A2-restricted CTL clone 
tested on autologous fibroblasts. E/T ratios were (a) 6:1, (b) 2:1, and (c) 
10:1, 5:1. 
of these cases (donor JB) the CTL response was clearly poly- 
clonal, containing two or more components,  each directed 
against a different target protein.  Where autologous fibro- 
blasts were not available (donors ER and RH), we were only 
able to map the major component within the CTL response 
by testing  on appropriately  HLA-matched  fibroblasts,  and 
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CTL components detected 
Donor  HLA type  EBV antigen  HLA restriction 
CMc  A2.1,  All; B8,  B44  EBNA 3A  B8 
EBNA 3B  All  and B8 
EBNA 3C  B44 
KS  A2.1,  All; B35,  B40  EBNA 3A  B35 
EBNA  3B  All 
LMP 2  ? 
SW  All,  A24; B7,  B35  EBNA 3A  B35 
EBNA 3B  All 
EBNA 3C  ? 
MS  A2.1;  B18,  B44  EBNA 3B  A2.1 
EBNA 3C  B44 
LMP 2  A2.1 
RaM  A2.1,  A24;  B7,  B44  EBNA 3A  A24 or B7 
EBNA 3B  A2.1 or B44 
EBNA 3C  A2.1 or B44 
LMP 2  A2.1 
LY  A1,  A24; B27.02,  B35  EBNA  2A  B27.02 
EBNA 3C  B27.02 
DH  A2.1,  All; B27.04,  B40  EBNA 3C  B27.04 
LMP 2  A2.1 
SC  A2.1;  B27.05  EBNA 3A  B27.05 
EBNA 3C  B27.05 
LMP 2  A2.1 
RT  A2.1,  A24; B27.05,  B35  EBNA 3C  B27.05 
LMP 2  A2.1 
WT  A2.1;  B14,  B15  EBNA 3C  A2.1 
LMP 2  A2.1 
IB  A2.1;  B7  EBNA 3C  B7 
LMP 2  A2.1 
CG  A25, A28; B39,  B62  EBNA 3C  ? 
LMP 2  ? 
ER*  A1, All; B8,  B22  EBNA 3C  B8 
KH*  A2.1,  A3; B7,  B39  EBNA 3C  B7 
JB*  A1; B7,  B8  EBNA 3C  B7 
Summary of analysis of polydonal CTL populations and derived CTL clones form 15 virus-immune donors. Note that the absence of appropriately 
matched target fibroblasts meant that in the case of donors KS, SW, and CG, certain EBV antigen-specific components of the CTL response could 
not be mapped to a restricting determinant,  while in the case of donor RM, some CTL components could be mapped to a haplotype but not to 
an individual restricting  determinant. 
* In the case of donors EK, RH, and JB, only the major component of the CTL response was analyzed; note that a coresident B8-restricted compo- 
nent present in donor JB CTL preparations did not map to any of the latent proteins tested. Likewise, EBV-specific  polyclonal CTLs from a 16th 
donor MR (HLA-A2, A29, B8, B40) did not map to any of the latent  proteins when  tested on autologous fibroblasts. 
minor components may well have gone unidentified in these 
cases. Second, all 15  donors had at least one component of 
their CTL response directed towards one of the EBNA 3 family 
of target proteins,  namely EBNA 3A,  3B,  or 3C.  In fact, 
such responses were often dominant, and EBNA 3C was a 
particularly frequent  target. In contrast, we did not detect 
CTL components directed against either EBNA  1,  EBNA 
LP, or LMP I  in any of the donors analyzed. Third, the ex- 
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specific response detectable on autologous or HLA-matched 
LCL targets did not recognize any of the current panel of 
EBV latent proteins expressed in autologous or HLA-matched 
fibroblasts. For example, the polyclonal CTLs reactivated from 
donor JB displayed both B7- and BS-restricted  lysis on LCL 
targets but, while the B7-restricted response could be mapped 
to EBNA 3C, no target protein could be identified for the 
BS-restricted response. A more extreme example involves the 
16th virus-immune donor tested, donor MR (HLA-A2, A29; 
BS, B40),  who generated polyclonal CTL preparations ac- 
tive against the autologous LCL but inactive against all recom- 
binant vaccinia-infected  fibroblast targets, whether autolo- 
gous or appropriately HLA matched (data  not shown). 
Finally, the analysis of CTL responses  from this panel of 
unrelated donors revealed several examples of responses map- 
ping to the same combination of EBV latent protein and HLA- 
restricting antigen. The particular combinations identified, 
and the number of donors giving a response to each combi- 
nation, are summarized in Table 2.  Thus, for example,  all 
three instances of All-restricted responses mapped to EBNA 
3B, all three B7-restricted responses mapped to EBNA 3C, 
and both B35-restricted response  mapped to EBNA 3A. In 
addition, there were seven donors in which an A2.1-restricted 
response was detectable,  and in every case LMP 2 was the 
principal target antigen. Also included in the analysis were 
four B27-positive  donors representing three of the known 
B27  subtypes: B27.02,  B27.04,  and B27.05  (30);  interest- 
ingly, each of these individuals mounted a detectable B27- 
restricted response and in each case the dominant EBV target 
antigen was identified as EBNA 3C. 
Discussion 
The operational specificity of EBV-induced CTL prepara- 
tions from LCL targets and their HLA class I-restricted func- 
tion has been known for some years, but the identity of the 
target antigens has always been in question (11). Following 
an earlier  study of type 1 EBV-specific CTL responses  (15, 
16), here we turned to the more general question of EBV 
target antigen choice among the broad range of virus-immune 
donors whose polyclonal CTL preparations show crossreac- 
tivity between EBV types 1 and 2 (15, 17). This work re- 
quired the construction of individual EBV/vaccinia recom- 
binants  for  each  of  the  eight  virus  latent  genes.  Such 
recombinants were generated using, for the most part, stan- 
dard protocols (see Fig. 1) and expression of the relevant EBV 
latent proteins confirmed on infection of cultured human 
fibroblasts  (Fig. 2). Fibroblasts were chosen since they repre- 
sented an accessible source of EBV-negative target cells that 
proved much more  susceptible  to vaccinia  virus infection 
than the other readily available alternative, namely phytohe- 
magglutinin-stimulated T lymphoblasts (R. J. Murray, un- 
published observations). Thereafter, our strategy was to ex- 
amine as large a range of donors as practical,  and in each case 
to concentrate the analysis on short-term polyclonal CTL lines 
assayed within 2-8 wk of in vitro reactivation. In this way 
we hoped to gain, for each donor, as representative  a view 
as possible  of those EBV latent proteins that provided the 
immunodominant targets for memory CTL responses. Where 
an individual component of the polyclonal response  could 
not be studied in isolation (for instance where aUogeneic fibro- 
blasts matched through the appropriate HLA antigen were 
Table  2.  Summary of EBV Target Protein/HLA Antigen Combinations Generating CTL  Targets* 
EBV target  proteins 
HLA antigen  EBNA 1  EBNA 2  EBNA 3A  EBNA 3B  EBNA 3C  EBNA LP  LMP 1  LMP 2 
All  0  0  0  + + +  0  0  0  0 
A2.1  0  0  0  +  +  0  0  +++++++ 
A2.1 or B44  0  0  0  +  +  0  0  0 
B44  0  0  0  0  + + +  0  0  0 
A24 or B7  0  0  +  0  0  0  0  0 
B7  0  0  0  0  +++  0  0  0 
B8  0  0  +  +  +  0  0  0 
B27.02  0  +  0  0  +  0  0  0 
B27.04  0  0  0  0  +  0  0  0 
B27.05  0  0  +  0  + +  0  0  0 
B35  0  0  + +  0  0  0  0  0 
Summary of data from the 14/15 donors in Table 1 where CTL components specific for individual EBV target proteins could be mapped to specific 
HLA-restricting determinants. Number of +  signs indicates the number of donors giving evidence of that particular EBV target protein/HLA anti- 
gen combination as a CTL target. 
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the clonal level. 
Despite the clear influence of HLA class I polymorphism 
on precise target antigen choice, the results show that for 
many donors the immunodominant CTL targets tend to be 
drawn from the same subset of  viral proteins. Thus, the major 
components of the CTL response could be mapped for 15/16 
donors tested, and in all 15 cases, these included one or more 
components directed against the EBNA 3A, 3B, 3C group 
of proteins;  indeed, EBNA 3C was a demonstrable  target, 
and often the most immunodominant target, in 14 of these 
individuals (Table 1). The above donors displayed a range of 
HLA types (including many of the alleles common in Cau- 
casian populations),  and examples were obtained  of four 
different HLA class I alleles presenting epitopes from EBNA 
3A, four different alleles  presenting epitopes from EBNA 3B, 
and seven different alleles presenting epitopes from EBNA 
3C (Table 2). In 9 of the 15 donors, the CTL response also 
contained a component directed against LMP 2, but here the 
frequency of such responses largely reflected the incidence 
with which one particular restricting allele, HLA-A2.1, was 
present in the group of donors analyzed (Table 1). We are 
confident that the positive results obtained with recombinant 
vaccinia virus-infected targets are meaningful because the cy- 
totoxicity experiments were always internally controlled, since 
the different  antigenic  reactivities within polyclonal CTL 
populations could be separated on the basis of their different 
HLA restrictions  (e.g., see Figs. 3-6), and because some of 
the above target antigen mappings  have been confirmed at 
the level of peptide epitopes (33, 34, and J. M. Brooks, un- 
published results). Since the type 1 EBNA 3A, 3B, and 3C 
proteins,  which frequently provided target epitopes in the 
present experiments,  show some sequence divergence from 
their type 2 counterparts (84%,  80%,  and 72%  identity, 
respectively, at the amino acid level; reference 14), it will be 
interesting to check to what extent CTL preparations that 
are crossreactive between virus types at the polyclonal level 
nevertheless contain some type-specific clonal reactivities. 
The work also revealed a number of negative results that 
are, in a sense, equally interesting. First, some polyclonal CTL 
preparations or components thereof  showed the classical HLA- 
restricted recognition of  LCL targets, yet did not map to any 
of the viral target antigens expressed by the vaccinia recom- 
binants (see Table 1, legend).  The same was also true of a 
number of CTL clones derived both from these and from 
other donors (35, and our unpublished results). Such effectors 
nevertheless appeared to be EBV specific in that they recog- 
nized the autologous LCL but not mitogen-stimulated lym- 
phoblasts, and were generated by a standard in vitro stimula- 
tion protocol to which only virus-immune donors have been 
found to respond (29). Further work is needed to identify 
the antigenic specificity of the above CTLs; one interesting 
possibility is that they are directed against epitopes of other 
EBV latent proteins whose constitutive expression in LCLs 
has to date gone undetected. 
Second, there were no examples within our group of 16 
donors of responses against three of the eight available latent 
proteins,  namely EBNA 1, EBNA LP, and LMP 1. For at 
least two of these antigens, this cannot be due to any failure 
of the recombinant vaccinia virus-infected cells to process 
the relevant protein, since, in a parallel study using the same 
recombinants,  examples were obtained  of rare CTL clones 
recognizing Vacc-E-LP-infected  targets and other clones recog- 
nizing Vacc-LMP-l-infected targets (35). In this context we 
would not expect EBNA LP to be a frequent target for T 
cell responses since the protein itself is largely comprised of 
a repeated 66-amino acid motif (31, 36), and therefore con- 
tains many fewer unique sequences than the other latent pro- 
teins. Responses to LMP 1 appear to be less frequent than 
our earlier studies based on LMP 1-transfected  target cells 
had implied (37). This emphasizes the difficulties inherent 
in T cell assays  involving stable LMP 1 transfectants as targets; 
increased lysis of LMP 1-positive clones versus controls may 
stem from immunologic.ally specific  recognition (38) or from 
a nonspecific sensitization to cytolysis due to LMP 1-induced 
changes in the target cell phenotype, in particular the surface 
adhesion molecule profile (39). 
The lack of  detectable CTL responses against EBNA 1 ap- 
pears particularly  significant since it was observed not just 
in our group of 16 virus-immune donors but also in a par- 
allel study involving a similar number of individuals  (35). 
Though it is still formally possible that some feature of  Vacc-E1 
virus infection impairs EBNA 1 processing and leads to false- 
negative results, the present data nevertheless suggest  that 
EBNA 1 contains few if any CTL epitopes. This is interesting 
in that EBNA 1, which is essential for stable episomal main- 
tenance of the viral genome in infected cells (40), is the only 
viral antigen to be expressed  in all known forms oFEBV latency 
(41-43). Indeed, we have argued that the ability of EBV to 
persist for long periods as an asymptomatic passenger in the 
human B lymphoid system depends upon a form of latency 
in which viral antigen expression is limited to EBNA 1 (44). 
If this is the case, the evolution of a functional EBNA 1 pro- 
tein lacking CTL epitopes would be of considerable advan- 
tage to the virus in establishing such a means of persistence. 
Further work needs to be carried out on donors representing 
a broader range of the HLA types before the trends suggested 
by the present work can be rigorously tested. Nevertheless, 
it is interesting to compare the present  results with those 
from the two other human viral systems where a systematic 
analysis of CTL target antigen choice has been carried out, 
namely influenza virus and HIV. The early work on influenza- 
specific CTL responses suggested, albeit on a small panel of 
donors, that target epitopes were frequently derived from  just 
3 of the 10 available viral antigens (45), and that responses 
restricted  through any one HLA class I antigen aU tended 
to be directed to the same immunodominant viral peptide 
(2, 46, 47). More recently, detailed analysis of HIV-induced 
responses has identified a much larger number ofpeptide epi- 
topes presented by each restricting antigen and a correspond- 
ingly much broader range of viral proteins from which epi- 
topes are derived (48, 49). It is still not clear to what extent 
these differences simply reflect the relative frequency of CTL 
precursors in the blood of immune donors,  and hence, the 
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systems. Our own results with EBV, a persistent lymphotropic 
agent, which like HIV can elicit relatively high numbers of 
CTL precursors in peripheral blood, also indicates the mul- 
ticomponent nature of each donor's CTL response and the 
ability of at least some HLA alleles to present epitopes from 
more than one viral target protein. In the EBV system, how- 
ever,  a hierarchy  of immunodominance  may be emerging 
among the viral target proteins; the EBNA 3A, 3B, 3C subset 
frequently provide CTL epitopes, while other proteins such 
as EBNA  1 are rarely if ever recognized. 
Finally, the present results bear upon another important 
aspect of EBV biology, namely, the ability of virus-induced 
CTL responses to act as a defence against EBV-positive malig- 
nant disease. Of the four types of human tumor most closely 
associated with  EBV,  only the immunoblastic  B cell lym- 
phomas seen in immunocompromised  patients express the 
full spectrum of virus latent proteins (23, 50), and therefore 
would be expected to remain  sensitive to CTL control on 
recovery of the patients'  T  cell response (51).  In contrast, 
EBV-positive Burkitt's lymphoma cells express only EBNA 
1 (41), and the present finding that this protein does not func- 
tion as a CTL target explains why Burkitt cell lines have proved 
insensitive to EBV-specific CTL preparations (52). Of partic- 
ular interest now are two other malignancies,  nasopharyn- 
geal carcinoma and the EBV-positive subset of Hodgkin's Dis- 
ease,  where  the  cells  display  a  third  form  of  latency 
characterized by expression of EBNA 1, LMP 1, and LMP 
2 (42, 43, 53; Deacon et al., manuscript submitted for publi- 
cation). Such tumors are therefore potentially susceptible to 
LMP-specific components of CTL responses. Given the fact, 
for instance, that LMP 2 is a target for HLA-A2.1-restricted 
responses in that most (but not all,  see donor CMc) A2.1- 
positive individuals,  it becomes important  to look for evi- 
dence of protection mediated by such HLA alleles. 
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